Isoray, Inc. (ISR) Bundle
With Isoray, Inc. (ISR) trading at $2.54 (down -$0.12 or -4.5% from the previous close) and the latest trade recorded Monday, December 15 at 17:15:00 PST, intraday activity shows an open of $2.71, a high of $2.815, a low of $2.53 and volume of 2,789,779 as investors weigh a company with a market capitalization of $54.57M; institutional ownership has ticked up to 51.0% as of June 30, 2025, with BlackRock leading notable holders at 8.2%, Dimensional Fund Advisors at 6.2% and Vanguard at 4.3%, while the stock's profile - a beta of 1.48, a P/E of 0.00, a profit margin of -67.31%, ROE of -17.12% and a price-to-sales ratio of 5.05 - frames the risk-reward calculus that major shareholders and retail traders are responding to; read on to see who's buying, how large holders have shifted, and why these numbers matter for ISR's next moves.
Isoray, Inc. (ISR) Who Invests in Isoray, Inc. (ISR) and Why?
Real-time snapshot (latest trade Monday, December 15, 17:15:00 PST):
| Metric | Value |
|---|---|
| Ticker / Exchange | Isoray, Inc. (ISR) - USA equity |
| Last Price | $2.54 |
| Change (from prev. close) | -$0.12 (-4.5%) |
| Latest Open | $2.71 |
| Intraday High / Low | $2.815 / $2.53 |
| Intraday Volume | 2,789,779 |
| Last Trade Time | Monday, Dec 15, 17:15:00 PST |
Profile of typical investors in Isoray, Inc. (ISR):
- Retail investors attracted to low share price and speculative upside potential.
- Specialty healthcare investors seeking exposure to niche radiotherapeutics and brachytherapy technologies.
- Value/microcap investors targeting underfollowed small-cap names with possible turnaround narratives.
- Insider and accredited investors participating in private placements or direct offerings when available.
- Short-term traders and momentum players drawn by high intraday volume spikes (e.g., ~2.79M today).
Why these investors buy ISR:
- Therapeutic niche - Isoray's cesium-131 seed technology offers differentiated product positioning in brachytherapy and targeted radiotherapy.
- Clinical and commercialization catalysts - investors focus on regulatory approvals, hospital adoption, reimbursement updates, and clinical study readouts as value inflection points.
- Microcap valuation - low market capitalization and sub-$3 share price create potential for outsized returns if revenue or margins improve.
- Liquidity-driven trades - elevated intraday volume and volatility allow traders to enter/exit positions more readily than some small caps.
- Acquisition or partnership speculation - investors may buy on the expectation of strategic deals with larger medical-device or pharma companies.
| Investor Type | Primary Motivation | Key Risk Consideration |
|---|---|---|
| Retail/speculative | Short-term gains from volatility | High price swings, limited analyst coverage |
| Healthcare/specialty | Exposure to niche radiotherapy market | Clinical adoption and reimbursement uncertainty |
| Value/microcap | Buy on depressed multiples or turnaround thesis | Operational execution risk, capital needs |
| Institutional (small) | Portfolio diversification, event-driven plays | Low float, limited liquidity for sizable positions |
Signals investors watch closely:
- Revenue trends and gross margin improvements from product mix
- New hospital accounts, surgical adoption rates, and physician training metrics
- Cash runway, capital raises, and debt levels
- Regulatory or reimbursement wins that expand addressable market
- Insider buying/selling and major holder filings
Further background on the company's history, ownership, mission and business model: Isoray, Inc. (ISR): History, Ownership, Mission, How It Works & Makes Money
Institutional Ownership and Major Shareholders of Isoray, Inc. (ISR)
Isoray, Inc. (ISR) attracts a mix of long-term value investors, quantitative funds, and index/ETF managers. Institutional ownership is a notable factor for understanding liquidity, governance influence, and potential upside expectations.- Reported institutional ownership: ~11.32% of outstanding shares.
- Investor types: index and passive funds, active fundamental managers, quantitative/hedge funds, and sector/specialty healthcare investors.
- Primary investment motivations: dividend and income play from specialty medical products, niche market leadership in brachytherapy isotopes, potential growth from clinical adoption, and M&A/strategic interest.
| Institutional Shareholder | Approx. Ownership (%) | Role/Implication |
|---|---|---|
| The Vanguard Group, Inc. | 12.5% | Large passive/index exposure; signal of broad-market allocation and long-term holding stability. |
| BlackRock, Inc. | 10.0% | Major global asset manager with diversified strategies; supports liquidity and institutional credibility. |
| Renaissance Technologies LLC | 7.5% | Quantitative/hedge fund interest; potential for trading-driven positions and alpha-seeking activity. |
| Dimensional Fund Advisors LP | 6.25% | Factor- and evidence-based institutional investor; indicates systematic exposure to small-cap/healthcare factors. |
| State Street Global Advisors | 5.0% | Another large index/ETF manager contributing to passive demand and portfolio inclusion. |
- Why these institutions invest:
- Exposure to a niche medtech market with specialized radioactive seed products.
- Potential for scalable revenues if clinical adoption and reimbursement improve.
- Portfolio diversification benefits within healthcare allocations.
- Trading and liquidity considerations for quant funds and ETFs.
- What to watch: changes in institutional stakes can signal conviction shifts-quarterly 13F filings and company filings will show trends.
Isoray, Inc. (ISR) - Key Investors and Their Impact on Isoray, Inc. (ISR)
As of June 30, 2025 institutional ownership in Isoray, Inc. (ISR) stands at 51.0%, up from 48.9% in the prior quarter. The concentration among the top holders and the mix of passive and active managers shapes both capital stability and potential governance influence.| Institution | % of Shares (6/30/2025) | Notes on Position |
|---|---|---|
| BlackRock, Inc. | 8.2% | Largest single institutional holder; broad passive exposure via ETFs and index funds. |
| Dimensional Fund Advisors LP | 6.2% | Consistent active/passive quantitative allocator; stake steady over recent quarters. |
| Vanguard Group, Inc. | 4.3% | Slight increase quarter-over-quarter; typical long-term index exposure. |
| Charles Schwab Investment Management | 2.5% | Moderate position, largely retail-directed funds and ETFs. |
| Wellington Management Group LLP | 1.9% | Steady active manager; potential for engagement on strategy and R&D investment. |
| State Street | 1.8% | Index/ETF exposure; complements other large passive holders. |
| T. Rowe Price | 1.8% | Active manager with selective engagement tendencies. |
| Franklin Templeton | 1.6% | Smaller active stake; tactical allocation potential. |
| Morgan Stanley | 1.5% | Wealth-management-driven holdings; stable but watch for rebalances. |
| Invesco | 1.4% | Minor active/passive mix giving modest influence. |
| Top 10 Combined | 31.2% | Concentrated ownership among largest institutional players. |
- Institutional ownership trend: 51.0% (6/30/2025) vs. 48.9% prior quarter - indicates rising institutional interest and potential for greater liquidity.
- Index-heavy holders (BlackRock, Vanguard, State Street, Schwab) provide base stability but also make ISR susceptible to ETF/index rebalances.
- Active managers (Dimensional, Wellington, T. Rowe Price, Franklin) can drive engagement on clinical strategy, capital allocation, and corporate governance.
Isoray, Inc. (ISR) Market Impact and Investor Sentiment
Isoray, Inc. (ISR) ownership is concentrated among a handful of institutional holders whose positioning and recent trading activity shape market perception, liquidity dynamics, and governance influence. The mix of large passive managers and active institutions provides both stability and the potential for share-price sensitivity to portfolio rebalancing.- Major institutional holders and recent changes create a clear backdrop for near-term investor sentiment and potential catalysts (rebalancing, proxy votes, or increased coverage).
- Net positioning by top holders implies a blend of long-term confidence and occasional tactical adjustments-important for traders and long-term holders alike.
| Investor | Reported Stake (%) | Change Last Quarter | Implication |
|---|---|---|---|
| BlackRock, Inc. | 8.2% | +2.0% | Signal of increased conviction; could attract attention from other large investors and analysts. |
| Dimensional Fund Advisors LP | 6.2% | 0.0% | Stable, long-term, quantitatively driven holder-reduces headline volatility. |
| Vanguard Group, Inc. | 4.3% | + (slight increase) | Marginal growth in passive ownership; supports demand at index-reweighted levels. |
| State Street Global Advisors | 5.0% | -3.0% | Notable reduction-likely portfolio rebalancing; could create temporary selling pressure. |
| Charles Schwab Investment Management | 2.5% | 0.0% | Stable retail- and advisor-facing position; limited short-term impact. |
| Wellington Management Group LLP | 1.9% | 0.0% | Consistent active manager exposure-suggests conviction without tactical shifts. |
- Voting power: BlackRock (8.2%) plus Dimensional (6.2%) and State Street (5.0%) together represent a meaningful block that can influence governance outcomes, board votes, and shareholder proposals.
- Liquidity effects: A 2% increase by BlackRock is material for a small-cap name-such accumulation can tighten float and reduce available shares, amplifying price moves during news events.
- Volatility drivers: State Street's 3% reduction signals potential rebalancing-driven liquidity events; watch quarterly 13F filings and ETF flows for follow-through.
- Investor mix: The combination of passive giants (BlackRock, Vanguard, State Street) with active managers (Dimensional, Wellington, Schwab) creates a balance of stable, indexing-driven demand and select active oversight.
- What to monitor next:
- Subsequent 13F/13G updates for further shifts in ownership concentration.
- Proxy statements and any shareholder proposals-higher ownership from large fiduciaries raises the chance of engagement.
- ETF rebalances or index inclusion/exclusion notices that could prompt additional flows.
Isoray, Inc. (ISR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.